Imipramine-associated hyperpigmentation

Annals of Pharmacotherapy

Volumn 37, Issue 6, 2003, Pages 825-828

  Dean, Charles E ^a,b   Grund, Frank M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Hyperpigmentation; Imipramine

Indexed keywords

IMIPRAMINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; FACIAL HYPERPIGMENTATION; HUMAN; HYPERPIGMENTATION; MALE; PARANOID SCHIZOPHRENIA; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; HUMANS; HYPERPIGMENTATION; IMIPRAMINE; MALE;

EID: 0038147265     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C431     Document Type: Article

References (11)

1. Greiner AC, Nicolson GA. New side-effects in prolonged chlorpromazine therapy. Can Psychiatr Assoc J 1965;10:109-11.
2. Hare PJ. Visage mauve? (? From Imipramine). Brit J Dermatol 1970;83: 420.
3. Hashimoto K, Joselow SA, Tye MJ. Imipramine hyperpigmentation: a slate-gray discoloration caused by long-term imipramine administration. J Am Acad Dermatol 1991;25:357-61.
4. Ming ME, Bhawan J, Stefanato CM, McCalmont TH, Cohen LM. Imipramine-induced hyperpigmentation: four cases and a review of the literature. J Am Acad Dermatol 1999;40:159-66.
5. Sicari MC, Lebwohl M, Baral J, Wexler P, Gordon RE, Phelps RG. Photoinduced dermal pigmentation in patients taking tricyclic antidepressants: histology, electron microscopy, and energy dispersive spectroscopy. J Am Acad Dermatol 1999;40:290-3.
6. Atkin DH, Fitzpatrick RE. Laser treatment of imipramine-induced hyperpigmentation. J Am Acad Dermatol 2000;43:77-80.
7. Angel TA, Stalkup JR, Hsu S. Photodistributed blue-gray pigmentation of the skin associated with long-term imipramine use. Int J Dermatol 2002;41:327-9.
8. Narurkar V, Smoller BR, Hu CH, Bauer EA. Desipramine-induced blue-gray photosensitive pigmentation. Arch Dermatol 1993;129:474-6.
9. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
10. Bolognia JL, Braverman IM. Skin manifestations of internal disease. In: Faucci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper KL, et al., eds. Harrison's principles of internal medicine. 14th ed. New York: McGraw-Hill, 1998:310-28.
11. Ewing DG, Einarson TR. Loxapine as an alternative to phenothiazines in a case of oculocutaneous skin pigmentation. Am J Psychiatry 1981; 138:1631-2.